New study tracks rare liver disease in kids to uncover clues
NCT ID NCT04181138
First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This study follows 1,000 children with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. Researchers will collect medical data, DNA, and symptom reports over time to understand how the disease progresses and affects daily life. The goal is to identify factors that may speed up the disease, helping doctors better manage it in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand PSC in children and identify factors that predict faster disease progression.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. Results may take years and might not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2021
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants are eligible for enrollment into the ChiLDReN PSC Study if they meet the inclusion criteria and if none of the exclusion criteria apply. Every effort will be made to enroll as diverse a patient population (racial, ethnic, sex, age, etc) as possible.
- Ages
-
2 to 25 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients with the clinical diagnosis of large or small duct PSC made at any time prior to enrollment are screened for eligibility to participate in this prospective cohort study. The site PI will determine eligibility following review of MRCP or ERCP images with the site radiologist to confirm presence of an abnormal cholangiogram at the time of diagnosis of large duct PSC. Liver histopathology obtained at the time of diagnosis of small duct PSC will be reviewed with the site pathologist prior to enrollment. Individuals must meet all of the Inclusion criteria in order to be eligible to participate in the study: 1. Aged 2 through 25 years at time of screening. 2. Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following: * Focal structuring of the bile duct(s) * Dominant stricture of the common bile duct * Saccular dilatation of bile duct(s) * Beaded appearance of bile duct(s) * Pruning appearance of the distal bile duct branches AND/OR 3. Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC: * Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR... * Definitive small duct PSC: Periductal fibrosis/ "onion skinning" around interlobular bile ducts or smaller profiles 4. Stated willingness to comply with all study procedures and availability for the duration of the study. 5. Able to provide informed consent/assent Participants for the imaging study are eligible if they are: 1. Aged 8 through 25 years at the time of screening 2. No absolute contraindication to MRI 3. No skin condition that could be aggravated by MREL 4. Meet all other eligibility criteria of the PSC Observational Study 5. For whom none of the exclusion criteria apply Exclusion Criteria: An individual who meets any of the following criteria at baseline will be excluded from participation in this study. 1. History of liver transplantation 2. History bone marrow transplantation 3. History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV/AIDS 4. History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH) 5. History of ischemic cholangitis 6. History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy 7. History of recurrent pyogenic cholangitis 8. History of biliary tract surgery for cholecystolithiasis prior to cholangiogram/liver biopsy evaluated to determine enrollment 9. History of biliary tract surgery for choledochal cyst 10. History of hepatocellular carcinoma, or hepatoblastoma 11. History of surgical biliary trauma 12. History of congenital cytomegalovirus (CMV) hepatitis 13. History of Sickle Cell Disease 14. History of cystic fibrosis, biliary atresia, Caroli disease/congenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3/MDR3 disease 15. History of cardiac hepatopathy. 16. History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency 17. Diagnosis of systemic lupus erythematosus (SLE) 18. Concurrent pregnancy at the time of enrollment -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangitis, sclerosing are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
9 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ann & Robert H Lurie Children's Hospital
RECRUITINGChicago, Illinois, 60611, United States
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
-
Children's Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
-
Children's Hospital of Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
-
Cincinnati Children's Hospital Medical
RECRUITINGCincinnati, Ohio, 45229, United States
-
Riley Hospital for Children
COMPLETEDIndianapolis, Indiana, 46202, United States
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
-
Texas Children's Hospital (Baylor College of Medicine)
RECRUITINGHouston, Texas, 77030, United States
-
The Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
The Hospital for Sick Children
COMPLETEDToronto, Ontario, M5G 1X8, Canada
-
The University of Utah
RECRUITINGSalt Lake City, Utah, 84113, United States
-
UPMC Children's Hospital of Pittsburgh
COMPLETEDPittsburgh, Pennsylvania, 15224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Device aims to keep donor livers healthier for transplant
- Massive Real-World database aims to map how chronic diseases interact
- Could type 1 diabetes hide liver problems in children?
- Can software make hospital pharmacists faster and safer?
- Can gut microbes hold the key to liver health?
- Can a shared data network transform care for kids with liver disease?